Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mauna Kea Technologies SAS

This article was originally published in Start Up

Executive Summary

Mauna Kea Technologies is developing Cellvizio, a tiny confocal laser microscopy system small enough to be inserted into the colon, the urinary tract, the lungs, deep in the brain, and other small spaces in the body. Today, every procedure in gastroenterology--a biopsy or a therapeutic intervention-- is already the second, third, or later step in a process that becomes cumbersome simply because clinicians can't get the relevant information from the first step, which is endoscopy. That's where Cellvizio brings advantages, providing a real-time, in vivo microscopic image of tissue to properly characterize it, so a gastroenterologist can both determine and efficiently carry out the proper course of treatment for a particular patient. Cellvizio's most compelling initial applications include the diagnosis of biliary strictures, Barrett's Esophagus, and colonoscopy.

You may also be interested in...



A Bright Future For Optical Imaging

One bright spot emerging in this otherwise lackluster economy is the market for optical imaging technologies. Optical imaging encompasses a wide array of current and emerging techniques that use light as the primary imaging modality to characterize local anatomy down to cellular and molecular levels.

NinePoint Medical Inc.

Over the past 20 years, the diagnosis of esophageal adenocarcinoma - the most common form of esophageal cancer - has doubled in the US and now stands at roughly 16,500 new cases each year. This dramatic increase is believed to be related to an increased incidence of gastroesophageal reflux disease (GERD) and obesity. Physicians agree that to slow the increase in this deadly cancer, detection at its earliest stages is critical. Unfortunately, the standard tools available to do this are less than ideal. NinePoint Medical has developed technology designed to detect precursors to esophageal cancer in real time, in vivo, using near-infrared light and complex computing algorithms.

EndoControl SAS

EndoControl's founders bet there are large market applications where surgeons will want to reach for a single-function, low-cost robot to lend a helping hand. EndoControl has developed the ViKY system, a motorized endoscope holder compatible with any endoscope, that responds to a surgeon's voice or foot command.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel